These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 20736456)
21. The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab. Benesova K; Forsterova K; Votavova H; Campr V; Stritesky J; Velenska Z; Prochazka B; Pytlik R; Trneny M Neoplasma; 2013; 60(1):68-73. PubMed ID: 23067219 [TBL] [Abstract][Full Text] [Related]
22. Tissue microarray in a subset of South African patients with DLBCL. Sissolak G; Wood L; Smith L; Chan JW; Armitage J; Jacobs P Transfus Apher Sci; 2013 Oct; 49(2):120-32. PubMed ID: 23942329 [TBL] [Abstract][Full Text] [Related]
23. Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases. Gong QX; Lu TX; Liu C; Wang Z; Liang JH; Xu W; Li JY; Zhang ZH; Chen Q Int J Clin Exp Pathol; 2015; 8(12):15825-35. PubMed ID: 26884853 [TBL] [Abstract][Full Text] [Related]
24. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992 [TBL] [Abstract][Full Text] [Related]
26. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967 [TBL] [Abstract][Full Text] [Related]
27. Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib. Balasubramanian S; Wang S; Major C; Hodkinson B; Schaffer M; Sehn LH; Johnson P; Zinzani PL; Carey J; Shreeve SM; Sun S; Gerecitano J; Vermeulen J; Staudt LM; Wilson W Br J Haematol; 2021 Jul; 194(1):83-91. PubMed ID: 33942292 [TBL] [Abstract][Full Text] [Related]
28. BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial. Petrella T; Copie-Bergman C; Brière J; Delarue R; Jardin F; Ruminy P; Thieblemont C; Figeac M; Canioni D; Feugier P; Fabiani B; Leroy K; Parrens M; André M; Haioun C; Salles GA; Gaulard P; Tilly H; Jais JP; Molina TJ Ann Oncol; 2017 May; 28(5):1042-1049. PubMed ID: 28327893 [TBL] [Abstract][Full Text] [Related]
29. Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation. Gu K; Weisenburger DD; Fu K; Chan WC; Greiner TC; Aoun P; Smith LM; Bast M; Liu Z; Bociek RG; Bierman PJ; Armitage JO; Vose JM Hematol Oncol; 2012 Sep; 30(3):143-9. PubMed ID: 22009820 [TBL] [Abstract][Full Text] [Related]
30. CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma. Xu J; Oki Y; Saksena A; Desai P; Lin P; Tang G; Yin CC; You MJ; Thakral B; Medeiros LJ; Li S Hum Pathol; 2017 Feb; 60():160-166. PubMed ID: 27816715 [TBL] [Abstract][Full Text] [Related]
31. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers. Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292 [TBL] [Abstract][Full Text] [Related]
32. Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm. Yoon N; Ahn S; Yong Yoo H; Jin Kim S; Seog Kim W; Hyeh Ko Y Oncotarget; 2017 Mar; 8(13):22014-22022. PubMed ID: 28423544 [TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537 [TBL] [Abstract][Full Text] [Related]
34. High concordance of gene expression profiling-correlated immunohistochemistry algorithms in diffuse large B-cell lymphoma, not otherwise specified. Hwang HS; Park CS; Yoon DH; Suh C; Huh J Am J Surg Pathol; 2014 Aug; 38(8):1046-57. PubMed ID: 24705314 [TBL] [Abstract][Full Text] [Related]
35. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664 [TBL] [Abstract][Full Text] [Related]
36. Impact of dose-dense immunochemotherapy on prognosis of germinal center and non germinal center origin of diffuse large B cell lymphoma. Rigacci L; Puccini B; Iovino L; Martelli M; Finolezzi E; DI Lollo S; Doria M; Bosi A J Chemother; 2011 Aug; 23(4):227-31. PubMed ID: 21803701 [TBL] [Abstract][Full Text] [Related]
37. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. Frei E; Visco C; Xu-Monette ZY; Dirnhofer S; Dybkær K; Orazi A; Bhagat G; Hsi ED; van Krieken JH; Ponzoni M; Go RS; Piris MA; Møller MB; Young KH; Tzankov A J Clin Pathol; 2013 Nov; 66(11):956-61. PubMed ID: 23775435 [TBL] [Abstract][Full Text] [Related]
38. [Primary gastrointestinal diffuse large B-cell lymphoma: an immunohistochemical and prognostic study of 90 cases]. Lin L; Min M; Bi CF; Wang XQ; Luo TY; Zhao S; Zhang WY; Liu WP Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):220-6. PubMed ID: 21615994 [TBL] [Abstract][Full Text] [Related]
39. Matched-pair analysis comparing the outcomes of T cell/histiocyte-rich large B cell lymphoma and diffuse large B cell lymphoma in patients treated with rituximab-CHOP. Kim YS; Ji JH; Ko YH; Kim SJ; Kim WS Acta Haematol; 2014; 131(3):156-61. PubMed ID: 24192382 [TBL] [Abstract][Full Text] [Related]
40. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ennishi D; Takeuchi K; Yokoyama M; Asai H; Mishima Y; Terui Y; Takahashi S; Komatsu H; Ikeda K; Yamaguchi M; Suzuki R; Tanimoto M; Hatake K Ann Oncol; 2008 Nov; 19(11):1921-6. PubMed ID: 18573805 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]